Back
Verve Therapeutics Quote, Financials, Valuation and Earnings
Invest. Do Good. Get Rewarded. Just $0.26/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
25
VERV
Verve Therapeutics
Last Price:
4.85
Seasonality Move:
-11.16%
7 Day Trial
ALL ACCESS PASS
$
7
Say this - unlock as much as $1,250 every Friday
Click here for full details.Verve Therapeutics Price Quote
$4.85
Verve Therapeutics Key Stats
Sell
25
Verve Therapeutics (VERV)
is a Sell
Day range:
$4.50 - $4.87
52-week range:
$4.31 - $19.34
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
16.60
P/B ratio:
0.81%
Volume:
1.1M
Avg. volume:
1.4M
1-year change:
-59.72%
Market cap:
$410.6M
Revenue:
$11.8M
EPS:
$-2.46
How Much Does Verve Therapeutics Make?
-
How Much Are Verve Therapeutics's Sales Annually?
VERV Revenues are $11.8M -
How Much Profit Does Verve Therapeutics's Make A Year?
VERV net income is -$200.1M
Is Verve Therapeutics Growing As A Company?
-
What Is Verve Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 1.2% -
What Is Verve Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Verve Therapeutics Stock Price Performance
-
Did Verve Therapeutics Stock Go Up Last Month?
Verve Therapeutics share price went down by -14.76% last month -
Did VERV's Share Price Rise Over The Last Year?
VERV share price fell by -59.72% over the past 1 year
What Is Verve Therapeutics 52-Week High & Low?
-
What Is Verve Therapeutics’s 52-Week High Share Price?
Verve Therapeutics has traded as high as $19.34 over the past 52 weeks -
What Is Verve Therapeutics’s 52-Week Low Share Price?
Verve Therapeutics has traded as low as $4.31 over the past 52 weeks
Verve Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Verve Therapeutics?
-
How Much Debt Does Verve Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Verve Therapeutics Have?
Cash and short term investments quarterly total is $539.9M -
What Is Verve Therapeutics’s Book Value Per Share?
Book value per share is 6.01
Is Verve Therapeutics Cash Flow Positive?
-
What Is VERV Cash Flow From Operations?
Cash flow from operations (TTM) is -$157.5M -
What Is Verve Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $201.4M -
What Is Verve Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $36.4M
Verve Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
VERV return on invested capital is -36.52% -
What Is Verve Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -28.45% -
What Is VERV Return On Equity?
ROE is a measure of profitability and is -36.52%
Verve Therapeutics Earnings Date & Stock Price
-
What Is Verve Therapeutics's Stock Price Today?
A single share of VERV can be purchased today for 4.85 -
What Is Verve Therapeutics’s Stock Symbol?
Verve Therapeutics trades on the nasdaq under the ticker symbol: VERV -
When Is Verve Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Verve Therapeutics is scheduled on February 27, 2025 -
When Is VERV's next ex-dividend date?
Verve Therapeutics's next ex-dividend date is November 25, 2024 -
How To Buy Verve Therapeutics Stock?
You can buy Verve Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Verve Therapeutics Competitors
-
Who Are Verve Therapeutics's Competitors?
Below is a list of companies who compete with Verve Therapeutics or are related in some way:
Verve Therapeutics Dividend Yield
-
What Is VERV Dividend Yield?
Verve Therapeutics’s dividend yield currently is 0% -
What Is Verve Therapeutics’s Payout Ratio?
Verve Therapeutics’s payout ratio is 0% -
When Did Verve Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 25, 2024 -
What Is Verve Therapeutics’s Dividend Per Share?
Verve Therapeutics pays a dividend of $0.00 per share
Verve Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 14.2% |
| Revenue: | 120.24% | 110.87% |
Analyst Recommendations
| Buy Recommendations: | 5 |
|---|---|
| Hold Recommendations: | 2 |
| Sell Recommendations: | 0 |
| Price Target: | 26.20 |
| Upside from Last Price: | 440.25% |